Better together! Thank you for your participation!

HOW means hands-on workshops! Useful skills & practical knowledge for daily clinical practice! University Hospital of Alexandroupolis.

CVD risk assessment, interactive cases and extensive discussions!

Visit to archaeological museum of Alexandroupolis: when medicine meets culture!

Interactive case-based learning and open discussions. Internal Medicine at its best!

Update! The program now includes the number of cases in each ICL session—get ready for dynamic, case-rich discussions!

Pleased to share our newly published paper entitled: "Clinical C3 Inhibition With AMY-101 Reveals Novel Insights Into IL-8–Driven Inflammation in COVID-19" onlinelibrary.wiley.com/doi/… This work, which was done a few years back, investigated the effects of AMY-101 in treating severe COVID-19, with a focus on understanding how C3 inhibition modulates key elements of IL-8–driven inflammation in these patients. It builds on the promising biological readouts of the ITHACA Phase II trial (see here: science.org/doi/10.1126/scia…) by providing new mechanistic insight that positions C3 activation at the heart of cytokine-driven proinflammatory pathways that can exacerbate lung pathology and neutrophil-driven thromboinflammation across various organs. The study showed that AMY-101 administration not only reduced markers of systemic inflammation, including NETs, CRP, and ferritin but also modulated IL-8, a major chemoattractant for neutrophils. It identified fibroblasts as a major source of increased IL-8 in severe COVID-19 and showed that C3 inhibition can broadly attenuate the proinflammatory consequences of the deregulated fibroblast-IL-8-neutrophil axis in severe COVID-19. These findings underscore the therapeutic potential of C3 targeting in COVID-19 and other neutrophil-driven inflammatory and fibrotic disorders. Moreover, they reveal a crucial mechanistic connection between C3 activation and IL-8–mediated immune responses. onlinelibrary.wiley.com/doi/…

Follow the discussion regarding "IL-1β/DNA complex elevation distinguishes #autoinflammatory disorders from #autoimmune and infectious diseases"! Two new Letters to the Editor and a Research Letter! 👉doi.org/10.1111/joim.13818 👉doi.org/10.1111/joim.13819 👉doi.org/10.1111/joim.13809

What a day to remember! The 16th International @AegeanConf Conference on #ComplementTherapeutics is dedicated to the pioneering work and groundbreaking contributions of @LambrisJD to #complementbiology & drug discovery #compstatins Happy 70th John!! What an inspiring journey!

Our novel findings for IL-1-mediated autoinflamnatory disorders. A promising method for differential diagnosis and targeted treatment! Many congrats to all collaborators!

Research abstract award in #ECIM2024 #EFIM. Really proud of our group!! Many congrats to all collaborators. My deep gratitude to PhD students Anastasia-Maria Natsi & Efstratios Gavriilidis, Dr. Christina Antoniadou and Prof. Konstantinos Ritis.

Ο καθηγητής Γ. Λάμπρης και το ελληνικό φάρμακο για την CoViD-19 iatronet.gr/article/119360/o… @LambrisJD #COVID19 #φάρμακο #θεραπεία #δοκιμή @duthnac

Honorary professorship bestowed on @LambrisJD by the Medical School of Democritus University of Thrace A true celebration of a long and exciting journey into science and discovery!! Thank you @PSkendros & Kosta Riti for hosting us at such an emotional event! @ComplementSoc

Inflamnation & Thrombosis meeting in Alexandroupolis, 22-23 September 2023. Final programme is released! Distinguished event for our academic community the Honorary Professor Ceremony, Prof JD Lambris Please check it out! 👇 az659834.vo.msecnd.net/event…

Deeply grateful for being bestowed upon a honorary professorship by the Demokritus University of Thrace! Looking forward to reuniting with a lot of dear friends and collaborators from Greece and abroad on this occasion.

Recent advances in #immunothrombosis, #complementbiology & more! #Inflammation & Thrombosis meeting in #Alexandroupolis, 22-23 September 2023. We are delighted to honor Professor @LambrisJD  for his groundbreaking contributions to the field. Check it out: pcoconvin.eventsair.com/Quic…

Happy to see @Amyndas joining forces with the @fibrotarget consortium in exploring the pathophysiology of #IBD #fibrosis and evaluating new therapeutic #targets! Let's try to help IBD #fibrosis patients who are in dire need of effective #therapies

Call for nominations for the Lambris Complement Training Award. Deadline to apply is June 1, 2023. complement.org/Lambris-Award… conta.cc/3GAMEpb

Great initiative by @LambrisJD and family & excellent opportunity for a prestigious #award that supports #earlystage #researchers & #trainees with potential to become the #complementbiology trailblazers of tomorrow! Please spread the word and apply!

A talk on "Complement therapeutics in hematological disorders: lessons from PNH" will be given by Prof. Antonio Maria Risitano Get registered at eutranslationalmedicine.org/… #hematological #disorder #infectioncontrol #virtualcongress #Medicalresearch #pharmaceutical